Company Valuation: ME Therapeutics Holdings Inc.

Data adjusted to current consolidation scope
Fiscal Period: August 2024 2025
Market Cap 1 69.27 118.4
Change - 70.86%
Enterprise Value (EV) 1 67.77 117
Change - 72.67%
P/E -51.7x -93.2x
PBR 46.9x 78.7x
PEG 0.6x 4.8x
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -49.4x -94.1x
EV / EBIT -49.4x -91.7x
EV / FCF - -
FCF Yield - -
Dividend per Share 2 - -
Rate of return - -
EPS 2 -0.0531 -0.0429
Distribution rate - -
Net sales - -
EBITDA 1 -1.373 -1.244
EBIT 1 -1.373 -1.276
Net income 1 -1.295 -1.193
Net Debt 1 -1.497 -1.331
Reference price 2 2.7500 4.0000
Nbr of stocks (in thousands) 25,189 29,589
Announcement Date 11/27/24 11/27/25
1CAD in Million2CAD
Estimates


P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
- - - - 38.67M
18.77x6.69x13.41x1.58% 65B
35.3x6.27x18.74x0.92% 51.2B
27.56x7.53x23.83x0.05% 51.19B
34.01x3.32x14.33x-.--% 43.93B
48.9x5.59x30.73x-.--% 41.96B
-18.47x189.62x-19.51x-.--% 38.14B
28.97x8.21x21.25x0.37% 33.24B
29.19x6.17x16.01x-.--% 25.2B
30.74x5.69x19.09x-.--% 22.5B
Average 26.11x 26.57x 15.32x 0.32% 37.24B
Weighted average by Cap. 25.97x 25.01x 15.48x 0.44%

Y-o-Y evolution of P/E

Valuation ratios - P/E - ME Therapeutics Holdings Inc.

Historical PBR trend

Valuation ratios - PBR - ME Therapeutics Holdings Inc.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - ME Therapeutics Holdings Inc.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - ME Therapeutics Holdings Inc.

  1. Stock Market
  2. Stocks
  3. METX Stock
  4. Valuation ME Therapeutics Holdings Inc.